Using ctDNA to Determine Therapies for Lung Cancer
This research is for people who have had lung cancer removed by surgery. Sometimes, even after successful surgery, a tiny amount of cancer might be left behind, which could lead to the cancer returning. This study uses a blood test to check for 'circulating tumour DNA' (ctDNA) – these are tiny pieces of cancer DNA found in the blood. If ctDNA is detected after surgery, the study aims to find out if giving additional treatments, like certain medications (such as Nivolumab or chemotherapy drugs like Pemetrexed, Gemcitabine, Cisplatin, Carboplatin), can reduce the chance of the cancer coming back. The main goal is to understand if this blood test can help doctors decide which patients would benefit most from extra treatment after surgery.
Em resumo
Sobre o que é este estudo?
When people have an early stage of a type of lung cancer called non-small cell lung cancer, the main treatment is usually an operation to remove the cancer. For many, this surgery is all that's needed to get rid of the cancer completely. However, sometimes a few cancer cells might remain in the body that are too small to be seen. If these cells are left behind, they can grow and cause the cancer to return later on. This is what doctors call a 'relapse'.
To try and spot these leftover cancer cells, scientists have developed a special blood test. This test looks for tiny fragments of DNA that cancer cells shed into the bloodstream, called 'circulating tumour DNA' (ctDNA). Think of it like a very sensitive detector looking for microscopic hints that cancer might still be present. Some early studies have suggested that if ctDNA is found in the blood after surgery, it might mean there's a higher chance of the cancer coming back.
This study wants to explore this idea further. If the ctDNA blood test shows that some cancer cells might still be around after surgery, the researchers want to see if giving extra treatment (which doctors call 'adjuvant treatment') can help prevent the cancer from returning. This could involve different medications. The hope is that this research will help doctors in the future to better understand who needs extra treatment after surgery and who doesn't, making treatments more targeted and effective.
Pontos principais
- This study uses a special blood test to find tiny cancer DNA fragments (ctDNA) after lung cancer surgery.
- If ctDNA is found, the study looks at whether extra treatments can help stop the cancer from returning.
- It aims to improve how doctors decide who needs more treatment after surgery for non-small cell lung cancer.
- Treatments include an immunotherapy drug (Nivolumab) or chemotherapy.
- You must have had complete surgery for your lung cancer and meet certain health criteria to be eligible.
- Participation involves regular hospital visits, blood tests, and receiving study treatment, with careful follow-up.
Quem pode ser elegível?
To join this study, you need to be at least 18 years old and generally feel well enough to take part. You must have had a complete operation to remove your non-small cell lung cancer, and this is the first time you've had treatment for this cancer (no previous chemotherapy or radiotherapy for this particular cancer). Your doctor will also check that your organs are working well enough for you to safely join the study.
A key part of joining is that the special ctDNA blood test must find traces of cancer DNA in your blood either before or after your surgery. This study is specifically for people where these tiny cancer DNA fragments are detected. If doctors would normally give you chemotherapy after surgery, you might not be suitable for this study.
If you are a woman who could become pregnant, or a man whose partner could become pregnant, you will need to agree to use effective contraception during the study and for a period afterwards to prevent pregnancy. This is a common precaution in many drug trials.
Este estudo pode ser adequado para você?
Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.
- Você tem 18 anos ou mais?
- Have you had surgery to completely remove your non-small cell lung cancer?
- Have you *not* had chemotherapy or radiotherapy for this particular lung cancer previously?
- Do you feel generally well and active enough for daily tasks?
- Has a ctDNA blood test (before or after surgery) found tiny traces of cancer DNA in your blood?
- Are you able to use effective contraception if you or your partner could become pregnant?
O que envolve a participação?
If you join this study, you will have several visits to the hospital for assessments. This will likely involve regular blood tests, including the special ctDNA test, and other checks to monitor your health and how the treatment is working. Depending on which treatment group you are in, you would receive either the immunotherapy drug Nivolumab or one of the chemotherapy combinations (Pemetrexed, Gemcitabine, Cisplatin, or Carboplatin). The specific schedule and number of treatments will be explained by the study team.
After your treatment period, you will have follow-up appointments to track your health and see if the cancer has returned. The study will likely involve regular check-ups for a significant period to monitor long-term outcomes. The study team will explain the full schedule of visits, medication administration, and follow-up, along with the total expected duration of your active participation and monitoring.
Riscos e benefícios potenciais
Localizações (1)
- Princess Margaret Cancer CentreCódigo postal verificadoToronto, Canadá· Recrutamento
Perguntas frequentes
What is 'ctDNA'?
CtDNA stands for 'circulating tumour DNA'. It's tiny pieces of genetic material that cancer cells release into your bloodstream. A special blood test can detect these tiny fragments.
Why is this blood test important?
This blood test might help doctors understand if there are still some cancer cells in your body after surgery, even if they're too small to see. This could help decide if you need more treatment to stop the cancer from coming back.
What is 'adjuvant treatment'?
Adjuvant treatment is extra treatment given after an initial main treatment (like surgery). The goal is to kill any remaining cancer cells and lower the risk of the cancer returning.
Eu definitivamente vou receber o novo medicamento?
Not necessarily. This study tests different treatments, including established chemotherapy drugs and an immunotherapy drug called Nivolumab. You will be assigned to a specific treatment plan determined by the study design.
Can I choose not to take part?
Absolutely. Taking part in a research study is completely voluntary. You can decide not to join, or you can withdraw at any time without it affecting your medical care.
Como saber mais
Natasha Leighl, M.D.
Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.
Interessado em participar?
Discussão
Discussão da comunidade
Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.